A detailed history of Headlands Technologies LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Headlands Technologies LLC holds 114,339 shares of BCRX stock, worth $809,520. This represents 0.07% of its overall portfolio holdings.

Number of Shares
114,339
Previous 55,221 107.06%
Holding current value
$809,520
Previous $494,000 75.51%
% of portfolio
0.07%
Previous 0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$7.55 - $9.06 $446,340 - $535,609
59,118 Added 107.06%
114,339 $867,000
Q2 2025

Aug 14, 2025

BUY
$6.41 - $11.19 $326,922 - $570,712
51,002 Added 1208.86%
55,221 $494,000
Q1 2025

May 09, 2025

BUY
$7.06 - $9.39 $29,786 - $39,616
4,219 New
4,219 $31,000
Q2 2024

Aug 07, 2024

BUY
$4.13 - $6.79 $69,177 - $113,732
16,750 New
16,750 $103,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.32B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.